StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc. (GILD) stock

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 12/30104% above fair value
$170.26+2.68 (+1.60%)

Close on Nov 17, 2026Market cap $211.18BP/E –Yield 1.86%

Gilead Sciences operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Gilead Sciences's operating cash flow for the twelve months ending Sep 30, 2026 was $14.48B, up 49.8% year over year. For fiscal 2025 it was $10.02B, down 7.5% from the year before. Over ten years it grew -7.2% a year on average. The highest annual figure on record is $21.25B in fiscal 2015.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$10.02B-7.5%
FY2024Dec 31, 2024$10.83B+35.2%
FY2023Dec 31, 2023$8.01B-11.8%
FY2022Dec 31, 2022$9.07B-20.3%
FY2021Dec 31, 2021$11.38B+39.4%
FY2020Dec 31, 2020$8.17B-10.7%
FY2019Dec 31, 2019$9.14B+8.9%
FY2018Dec 31, 2018$8.40B-29.4%
FY2017Dec 31, 2017$11.90B-30.2%
FY2016Dec 31, 2016$17.05B-19.8%
FY2015Dec 31, 2015$21.25B+65.8%
FY2014Dec 31, 2014$12.82B+312.8%
FY2013Dec 31, 2013$3.11B-2.8%
FY2012Dec 31, 2012$3.20B-12.2%
FY2011Dec 31, 2011$3.64B+28.4%
FY2010Dec 31, 2010$2.83B-8.0%
FY2009Dec 31, 2009$3.08B+43.7%
FY2008Dec 31, 2008$2.14B+28.4%
FY2007Dec 31, 2007$1.67B–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$5.04B+22.6%
Q2 FY2026Jun 30, 2026$3.57B+332.0%
Q1 FY2026Mar 31, 2026$2.54B+44.8%
Q4 FY2025Dec 31, 2025$3.33B+11.8%
Q3 FY2025Sep 30, 2025$4.11B-4.7%
Q2 FY2025Jun 30, 2025$827.00M-37.6%
Q1 FY2025Mar 31, 2025$1.76B-20.8%
Q4 FY2024Dec 31, 2024$2.98B+37.2%
Q3 FY2024Sep 30, 2024$4.31B+145.5%
Q2 FY2024Jun 30, 2024$1.33B-43.3%
Q1 FY2024Mar 31, 2024$2.22B+27.2%
Q4 FY2023Dec 31, 2023$2.17B-15.5%
Q3 FY2023Sep 30, 2023$1.76B-38.7%
Q2 FY2023Jun 30, 2023$2.34B+29.7%
Q1 FY2023Mar 31, 2023$1.74B-5.2%
Q4 FY2022Dec 31, 2022$2.57B-19.9%
Q3 FY2022Sep 30, 2022$2.86B-12.0%
Q2 FY2022Jun 30, 2022$1.80B-22.2%
Q1 FY2022Mar 31, 2022$1.84B-29.5%
Q4 FY2021Dec 31, 2021$3.21B+67.3%
Q3 FY2021Sep 30, 2021$3.25B+44.6%
Q2 FY2021Jun 30, 2021$2.32B-9.7%
Q1 FY2021Mar 31, 2021$2.61B+81.8%
Q4 FY2020Dec 31, 2020$1.92B-25.7%
Q3 FY2020Sep 30, 2020$2.25B-14.9%
Q2 FY2020Jun 30, 2020$2.57B+9.6%
Q1 FY2020Mar 31, 2020$1.44B-8.9%
Q4 FY2019Dec 31, 2019$2.58B+10.0%
Q3 FY2019Sep 30, 2019$2.65B+19.6%
Q2 FY2019Jun 30, 2019$2.34B+48.9%
Q1 FY2019Mar 31, 2019$1.58B-30.5%
Q4 FY2018Dec 31, 2018$2.35B-14.8%
Q3 FY2018Sep 30, 2018$2.21B-17.9%
Q2 FY2018Jun 30, 2018$1.57B-55.4%
Q1 FY2018Mar 31, 2018$2.27B-22.4%
Q4 FY2017Dec 31, 2017$2.75B-22.2%
Q3 FY2017Sep 30, 2017$2.69B–
Q2 FY2017Jun 30, 2017$3.53B–
Q1 FY2017Mar 31, 2017$2.93B–
Q4 FY2016Dec 31, 2016$3.54B–

More Gilead Sciences figures

See a number that looks wrong?